Your browser doesn't support javascript.
loading
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
Holmström, Tim H; Moilanen, Anu-Maarit; Ikonen, Tarja; Björkman, Mari L; Linnanen, Tero; Wohlfahrt, Gerd; Karlsson, Stefan; Oksala, Riikka; Korjamo, Timo; Samajdar, Susanta; Rajagopalan, Srinivasan; Chelur, Shekar; Narayanan, Kishore; Ramachandra, Raghuveer K; Mani, Jiju; Nair, Rashmi; Gowda, Nagaraj; Anthony, Thomas; Dhodheri, Samiulla; Mukherjee, Subhendu; Ujjinamatada, Ravi K; Srinivas, Nanduri; Ramachandra, Murali; Kallio, Pekka J.
Afiliação
  • Holmström TH; Orion Corporation Orion Pharma, Finland. tim.holmstrom@orionpharma.com.
  • Moilanen AM; Orion Corporation Orion Pharma, Finland.
  • Ikonen T; Orion Corporation Orion Pharma, Finland.
  • Björkman ML; Orion Corporation Orion Pharma, Finland.
  • Linnanen T; Orion Corporation Orion Pharma, Finland.
  • Wohlfahrt G; Orion Corporation Orion Pharma, Finland.
  • Karlsson S; Orion Corporation Orion Pharma, Finland.
  • Oksala R; Orion Corporation Orion Pharma, Finland.
  • Korjamo T; Orion Corporation Orion Pharma, Finland.
  • Samajdar S; Aurigene Discovery Technologies Limited, India.
  • Rajagopalan S; Aurigene Discovery Technologies Limited, India.
  • Chelur S; Aurigene Discovery Technologies Limited, India.
  • Narayanan K; Aurigene Discovery Technologies Limited, India.
  • Ramachandra RK; Aurigene Discovery Technologies Limited, India.
  • Mani J; Aurigene Discovery Technologies Limited, India.
  • Nair R; Aurigene Discovery Technologies Limited, India.
  • Gowda N; Aurigene Discovery Technologies Limited, India.
  • Anthony T; Aurigene Discovery Technologies Limited, India.
  • Dhodheri S; Aurigene Discovery Technologies Limited, India.
  • Mukherjee S; Aurigene Discovery Technologies Limited, India.
  • Ujjinamatada RK; Aurigene Discovery Technologies Limited, India.
  • Srinivas N; Aurigene Discovery Technologies Limited, India.
  • Ramachandra M; Aurigene Discovery Technologies Limited, India.
  • Kallio PJ; Orion Corporation Orion Pharma, Finland.
Mol Cancer Ther ; 18(1): 28-38, 2019 01.
Article em En | MEDLINE | ID: mdl-30301864
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Linfócitos T / Inibidores de Proteínas Quinases / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Neoplasias Renais Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Linfócitos T / Inibidores de Proteínas Quinases / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Neoplasias Renais Idioma: En Ano de publicação: 2019 Tipo de documento: Article